James Wm. Forsythe, MD, HMD Board Certified Medical Oncologist Board Certified Internal Medicine Certified in Homeopathy

Immune Protocol ™ Out-Come Based Investigation

1700 Patients - 96 Months From 03/2012 – 03/2020 Using Chemosensitivity Testing and Lite LDIPT ™

ForsytheCancerCare.com

James Wm Forsythe, MD, HMD Board Certified Internal Medicine, QA/UR Board Certified Medical Oncology Certified in Homeopathy Board Eligible: Pathology, Gerontology, Anti-Aging Medicine

This presentation has been peer-reviewed for fair and balanced evidencebased medicine.

Status of FDA devices used for the material being presented: NA/Non-Clinical

No Financial interests with any pharmaceutical company: NA/Non-Clinical

Status of off-label use of devices, drugs or other materials that constitute the subject of this presentation: Discuss off-label use of chemotherapy drugs for different cancers. 2

Alternative Cancer Treatments 2020 The Immune Protocol™ + The Lite LDIPT Protocol ™

- Top Ten Take Home Points:
- **1.** Integrative cancer medicine combines conventional and alternative treatments
- 2. Hope in victory over cancer with integrative cancer therapies
- 3. Genomic Testing (CST) on whole blood isolates circulating tumor stem blood cells
- 4. Genomic testing offers a blue print for individual's cancer treatments
- 5. Genomic testing defines top chemo agents most effective in the treatment of each patient's cancer as well as hormone blockers
- 6. Genomic testing isolates supplements, herbs and vitamins that are most effective in the treatment of one's cancer
- 7. Insulin Potentiated Therapy (IPT) uses insulin as its target agent
- 8. CST + IPT + Lipoic –Acid-Palladium (LAPd) Compound produces higher survivorship rates
- 9. Immune Protocol™
 - shows overall survivorship rate of 70% over a 96 month period in 1700 Stage
 - IV cancer patients calculated from 03/12-03/20
- **10.** Freedom to choose alternative cancer treatments is your right
- 11. CTCs is best CA marker

Past and Ongoing Clinical Outcome – Based Cancer Studies

TIME	PRODUCT	Mode of Action
2002-2003	Paw-paw NSP	Energetics
2004-2006	Lipoic-Acid- Palladium (LAPd)	Hyper-energizes Promotes Apoptosis
2012- Present 8 years	Immune Protocol [™] + CST + Lite LDIPT Protocol [™]	Immune Boosters + CST + Lite LDIPT

FINDING THE "TRIGGER" FOR CANCER

Potential Cause(s) Heavy Metal Toxins Chemical Toxins Allergies: food and inhalants Viral and Fungal Etiologies Immune Competence Hormonal Imbalance

Hair, Blood, Urine Blood ELISA Blood & Skin HPV, HIV, EBV,HEP B/C Lymph Subset & NKC panels Saliva & Blood

Tests


Tumor Markers*

1. Bladder - NMP-22, BTA 2. Breast - CEA, CA 27-29, CA-15-3 3. Colorectal – CEA, CA 19-9, 5HIAA (Carcinoids) 4. Esophagus – CEA, CA 19-9 5. Gastric – CEA, CA 19-9 6. Liver – AFP, CEA, & CA19-9 7. Lung – CEA, CA 19-9 8. Lymphomas - ESR, LDH, Beta – 2 Microglobulin 9. Myeloma - B2MG, SPE, LDH, ESR **10.Pancreas – CEA, CA 19-9** 11.Prostate – PSA, Free PSA 12.Ovary – CA-125 13.Testes – AFP, HCG 14. CTCs-quantitative # * No tumor markers for sarcomas, H/N, RCC, CNS

New Technology – Genomic Chemo-Sensitivity Testing (CST)

- Performed on whole blood
- High Tech Labs World-Wide (Korea, Germany, Greece)
- Cancer cells harvested from blood grown in vitro
- Subjected to genetic decoding
- Results include: > 50 varieties of chemo drugs, targeted agents and > 70 individual supplements
- Protocol written marrying best drugs with effective supplements and hormonal blockers
- Produces <u>blueprint</u> for patient's specific cancer
- The Lite Low-dose fractionated IPT ™ treatment offered
- Full dose chemotherapy offered (required)

Genomic Graphic Results



Genomic Graphic Results

Supplement Grafting Class III

1. Melatonin							
2. Naltrexone							
3. Resveratrol	Π						
4. Indol 3 Carbinol							
5. Paw-Paw							
6. Quercetin							
7. Salvestrol	Π						
8. Curcumin							
9. Arabinogalactan							
10. Aromat8-PN							
11. Dextrol							
	0	10	2	2	30	40	50

Benefits of CST Testing

Blueprint for patient's chemo treatment

- Identify the best hormonal and supplement therapies
- Identify the best targeted drugs (Immunotherapy)
- Identify the best chemotherapy agents
- Identify the best hormonal and HER-2 Blockers
- Identify CTC number on each cancer

DX:	LUNG CA	Service Color	Allergies: DAIRY					
Phone:	11	Cell:	Email:					
Ht:	5'4"		Wt:	163 LBS		BSA (m2):		
NY N	Zofran 8n	ng	Preme	dications	Chemoth	erapy IPT	IT IV Infus	ion:
	Anzemet	100mg	Be	nadryl 25m	ng	Dexameth	asone 4mg	
CHEMO	CISPLATI	IN	R. Martin	1			12MG/M2 BI	W 3 WK
1000	Dilute in	250ml NS an	d infuse > 3	0 minutes				
CHEMO	TAXOTER	RE					6MG/M2 BI	W 3 WK
	Dilute in 2	50ml NS and	infuse > 30	minutes wit	h 5U Regula	r Insulin	Sec. Alter	
	1. FBS ch	eck > 4xs d	luring to: B	S< 40 give	50% Dextr	rose IVP		
	2. Schedu	ule for IPT a	nd Forsyth	e Immune	Protocol (F	IP):		in the
x	IPT:	2 x/wk x 3	wks: + F	IP: 3 x/w	k x 3 wks		Service of the	1. 200
	IPT:	3 x/wk x 2	wks: + F	IP: 2 x/w	k x 2 wks		S. C. Mark	1.7
	IPT:	2 x/wk x 3	8 wks: + F	IP: 1 x/w	k x 2 wks	1		1.1.1
	3. CTC's	5						
ORAL	MTX 2.5	mg po MW	F x 3 mos		(Steel	Ser 22	ERLOTINIE gd x 3 mos	
	CBC gow	CMP mo	CEA mo	CA 19-9	AFP mo	CA 125	PSA mo	CA 27-29
	x	x	x	X	the second	1.		
	Chemo			%	Suppler	nents	121	%
	1	Cisplati	n	82	1	Agaricu	IS	15
	2	Carbop	a	81	2	Artcin		30
	3	Oxalipla	astin	75	3	Artesur	nate	30
	4	MITOC		75	4	Ascorb	ic Acid	35
	5	Nedapla	at		5	Butyric	Acid	20
	6	Taxol		80	6	C-Stati	n	30
	7	Taxote	re	82	7	Frankir	ncense	10
	8	Abraxa	ne	80	8	Mito Bo	poster	30
	9	VCR	3.20 4	80	9	Mitocho	ondria	25.
	10	VLB	and the	75	10	OxaLoacetate		15
	11	Vinorel	bine	82	11	Super A	rtemsinin	30
	12	MTX		70	12	Mistlete	be	10

Potential Effectiveness of Mutiple Cancer Protocols

Based on numbers from the R.G.C.C.-Research Genetic Cancer Centre, LTD

Patient:

Date: 22 Jan 2015

	RGCC	Combi	ned Effectiven	ess
	reported individual effectiveness	Simple Math (100% "follow-on effective")	75% "follow-on effective"	50% "follow-on effective"
[/] Chemo agents recommended				
Vinorelbine	81.0%	81.0%	81.0%	81.0%
Gemzar	81.0%	96.4%	92.5%	88.7%
Supplements recommended				
Artemisia	50.0%	98.2%	95.3%	91.5%
Bioflavonoid Complex/Que	10.0%	98.4%	95.7%	91.9%
Buffered C/ Vit C	15.0%	98.6%	96.2%	92.5%
Curcumax/Curcumin	20.0%	98.9%	96.7%	93.3%
DIMension 3/1-3-C	20.0%	99.1%	97.2%	94.0%
Paw Paw	15.0%	99.2%	97.5%	94.4%
C-Statin	25.0%	99.4%	98.0%	95.1%
Genistein	10.0%	99.5%	98.2%	95.4%
Thymus Ext/Thymex	10.0%	99.5%	98.3%	95.6%
Mistletoe Extact	15.0%	99.6%	98.5%	95.9%
Oleander Extract	15.0%	99.7%	98.7%	96.2%
Final estimate		99.7%	98.7%	96.2%

1

Standard 3 Weeks The Immune Protocol ™The Lite LDIPT Protocol ™ (03/12-03/20)

- Monday Immune Protocol ™ + LAPd IV
- Tuesday Lite LDIPT [™] + L-Glutathione IV
- Wednesday Super "C" 50 grams + H2O2 IV
- Thursday Lite LDIPT [™] + L-Glutathione IV
- Friday Immune Protocol ™ + LAPd
- After TX: (No PET, CAT or Bone Scans)
- DC to home on maintenance CT / Targeted drugs or IPT treatments for 3 mos-return visits after 3 mos
- Long term maintenance with Cannabis Oils; 6-24 mos
- Optional maintenance with Essential Oils; or FENBEN
- Monitor appropriate X-Rays, MRIs, US's, and CXR's

TESTING LAB TYPICAL GENE PROBES

TS	DNA	EGF
DHFR	M-TRANS	TGFb
TUBULIN	O6AT	MMP9
ΤΟΡΟ	DNAdeam	NUC-REDUCT
SHMT	MPP	COX-2
DPD	LRP	S-lox
IP	GST	SS-r
p27	BEGF	C-erb2
p53	PDGF	ER/PR

Genomic Testing Sample Recommendations (Natural)

Artemesia	LAPd	Salvestrol	LAPD
H2O2	D3	Uncara tom	Paw-Paw
Vitamin C	Quercetin	Angiostop	DCA
Vitamin B6	LDN	Noni juice	Vitamin B3
Mistletoe	Genistein	Acetogen	Apigenin
Ukrain	Carnivora	Cesium Cl	Vitamin E
Vitamin B17	COQ 10	Mitake	SOD
Coll Silver	Essiac tea	Curcumin	Selenium
DIM	Mod cit pec	Green tea	Aloe Vera
C-Statin	IP-6	Melatonin	Doxycycline

Chemosensitivity Testing Commonly Recorded Supplements

Quercetin	LAPd
Artemesia	Salvestrol
Vitamin C /B17/CO-Q10	Ukrain
C-Statin	DIM
Vitamin D3	Paw-Paw
Mistletoe	Curcumin

Immune Protocol Prospective Study Total Survivors Lite LDIPT Protocols + CST 1700 Patients 96 Months Study

<u>Survivors: 1190/1700</u> Percent Survivors = 70%


Response Rates at 96 months 1700 patients with Stage IV Cancers

Cancer Origin	Total #	% Survivors
Bladder	32	57
Breast	400	75
Colorectal	120	50
Gastric/Esop	30	23
Head/Neck	52	50
Lung	60	25
Myeloma	46	78

Response Rates at 96 months 1700 patients with Stage IV Cancers*

Cancer Origin	Total #	% Survivors
NHL/CLL/HD	59	85
Ovary/PPC	43	72
PAN/GB	46	50
Prostate	86	91
Renal Cell	16	25
Sarcomas	24	33
Thyroid	12	100
UT/CX	40	64

*Cancers <10 patients in number not calculated



Stage IV Breast Cancer Survival 1700 Patients 96 Months Study

Cases	Patients' Survival	Percent Survival
400	300	75

Stage IV Lung Cancer Survival 1700 Patients 96 Months Study

Cases	Patients' Survival	Percent Survival
60	15	25

Stage IV Prostate Cancer Survival 1700 Patients 96 Months Study

Cases	Patients' Survival	Percent Survival
86	80	91

Stage IV Colorectal Cancer Survival 1700 Patients 96 Months Study

Cases	Patients' Survival	Percent Survival
120	60	50

Conclusions: Conventional Chemotherapy Results

* Five year Overall Survival Rate (OS) Stage IV Cancers	Adjuvant Cytotoxic Chemotherapy for 22 major adult malignancies
United States	2.1%
Australia	2.3%

*Reported from the Journal of Clinical Oncology (2004) 16:549-560

Clinical Oncology (2004) 16: 549-560 doi:10.1016/j.clon.2004.06.007

Overview

The Contribution of Cytotoxic Chemotherapy to 5-year Survival in Adult Malignancies

Graeme Morgan", Robyn Ward†, Michael Barton.

*Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW; †Department of Medical Oncology, St Vincent's Hospital, Sydney, NSW; ‡Collaboration for Cancer

Outcomes Research and Evaluation, Liverpool Health Service, Sydney, NSW, Australia

ABSTRACT:

٩

Aims: The debate on the funding and availability of cytotoxic drugs raises questions about the contribution of curative or adjuvant cytotoxic chemotherapy to survival in adult cancer patients.

Materials and methods: We undertook a literature search for randomised clinical trials reporting a 5-year survival benefit attributable solely to cytotoxic chemotherapy in adult malignancies. The total number of newly diagnosed cancer patients for 22 major adult malignancies was determined from cancer registry data in Australia and from the Surveillance Epidemiology and End Results data in the USA for 1998. For each malignancy, the absolute number to benefit was the product of (a) the total number of persons with that malignancy; (b) the proportion or subgroup(s) of that malignancy showing a benefit; and (c) the percentage increase in 5-year survival due solely to cytotoxic chemotherapy. The overall contribution was the sum total of the absolute numbers showing a 5-year survival benefit expressed as a percentage of the total number for the 22 malignancies.

Results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.

Conclusion: As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic elemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required. Morgan, G. et al. (2004). Clinical Oncology 16, 540-560

The Immune Protocol ™/ CST + Lite LDIPT Protocol ™ Summary 1700 Patients over 96 months

- The most important new addition to The Immune Protocol ™ program is the addition of chemosensitivity testing - different families of chemotherapy agents along with 50 separate supplements performed on whole blood genetic decoding.
- The <u>96 month</u> results on <u>1700</u> patients shows a survivorship (OS) of <u>70%</u> – in a Prospective Study.

The Immune Protocol ™/ CST + Lite LDIPT Protocol ™ Summary 1700 Patients over 96 months (Continued)

- The Immune Protocol ™ / Lite LDIPT Protocol ™ program offers patients a full spectrum menu which is based on their own choices guided by chemosensitivity, supplement sensitivity testing and hormonal sensitivities.
- Full dose toxic chemotherapy should no longer be considered
- The results show that chemo drugs should be reduced by 90%

Adverse Reactions to Full Dose Conventional Chemotherapy

This is true provided that this improvement is not gained at the expense of toxic chemotherapy or radiation therapy leaving the patient with many of the following adverse side effects:

- Chemo Brain Syndrome/Chonic Depression
- Painful Neuropathies
- Cardiomyopathies
- Renal Failure / Platinum toxicities /Hepatic Failure
- Severe Pancytopenias
- Pulmonary Fibrosis
- Devastating Fatigue, Anorexia and Wasting Syndromes
- Osteoarthritis, myalgias, osteoporosis
- Severe dermatoses
- Death

This study shows that the *"cure or kill"* approach to advanced full dose cancer treatment is not the answer.


New Horizons in Integrative Medical Oncology

- Artesunate IV
- Atorvastatin
- Cannabis Oil
- Curcumin IV Protocol
- DCA + LAPd IV Protocol
- Dipyrimadole
- Doxycycline
- Febendazole

New Horizons in Integrative Medical Oncology

- Essential Oils
- Far-Infrared Saunas and Bio-mats
- Melatonin
- Metformin
- Mushrooms: Agaricus / Cordyceps / Ganoderma
- NALTREXONE-Low Dose
- Scorpion/ Spider Venoms /Bee Stings
- Tagomet





Forsythe Cancer Care Center James W Forsythe, MD, HMD 775.827.0707 DrForsythe.com ForsytheCancerCare@gmail.com 521 Hammill Lane, Reno, NV 89511